Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Inc. (CRMD) CEO Khoso Baluch on Q4 2020 Results - Earnings Call Transcript
06:10pm, Tuesday, 30'th Mar 2021
CorMedix Inc. (CRMD) CEO Khoso Baluch on Q4 2020 Results - Earnings Call Transcript
CorMedix Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
04:05pm, Tuesday, 30'th Mar 2021
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMD
03:00am, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMD
09:57pm, Sunday, 21'st Mar 2021
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMD
04:49pm, Thursday, 18'th Mar 2021
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
08:30am, Monday, 15'th Mar 2021
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMD
09:36pm, Sunday, 14'th Mar 2021
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are
CorMedix: Resolvable CRL And Low Price Make It Attractive
02:46pm, Friday, 12'th Mar 2021
CRMD received a CRL that looks resolvable.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMD
05:35am, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised t
CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations
08:30am, Thursday, 11'th Mar 2021
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
CorMedix Inc. to Host Regulatory Update Conference Call
05:00pm, Monday, 08'th Mar 2021
BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline
01:38pm, Monday, 08'th Mar 2021
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMD
06:28pm, Sunday, 07'th Mar 2021
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are a
Why CorMedix Stock Is Crashing Today
12:55pm, Monday, 01'st Mar 2021
The FDA gave a thumbs-down to CorMedix's antibacterial/anti-fungal catheter lock.
CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock Solution
08:30am, Monday, 01'st Mar 2021
BERKELEY HEIGHTS, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
